Monitor the closing of the offering and the actual amount raised. If the offering is undersubscribed, the company may need to raise additional capital sooner, increasing dilution risk. The warrants (exercise price undisclosed) add future overhang. Watch for any subsequent financing or clinical trial updates that could affect the stock price.
Executive Summary
Creative Medical Technology Holdings (CELZ) filed Amendment No. 1 to its S-1 for a best-efforts public offering of up to 3,045,685 shares of common stock and 6,091,371 warrants at an assumed combined price of $1.97 per share, with estimated net proceeds of ~$5.34M. The clinical-stage biotech has no approved products, minimal revenue, and an accumulated deficit of ~$72M. The offering has no minimum, so proceeds could be substantially less, and existing shareholders face immediate dilution of $0.37 per share.
Key Facts
- Best-efforts offering with no minimum — actual proceeds may be far below the $5.34M estimate
- Immediate dilution of $0.37 per share for new investors (19% dilution from current 3.7M shares outstanding)
- Company has no approved products, minimal revenue, and an accumulated deficit of ~$72M as of March 31, 2026
- Cash position of $5.7M as of March 31, 2026; pro forma cash would be ~$11.1M if fully sold
- Public warrants and pre-funded warrants will not be listed on any exchange, creating liquidity risk
- Officers and directors subject to 90-day lock-up; company restricted from variable-rate transactions for 180 days
- Offering ends no later than July 15, 2026; shares underlying warrants offered continuously under Rule 415
Financial Impact
Up to ~$5.34M net proceeds if fully sold, but no minimum means proceeds could be negligible. Immediate dilution of $0.37 per share (19% of offering price).
Risk Factors
- Best-efforts structure with no minimum — may raise far less than needed
- Immediate and substantial dilution to existing shareholders
- No trading market for warrants, limiting exit options for investors
- Clinical-stage company with no approved products and history of losses
- Potential delisting from Nasdaq if bid price falls below $1.00
- Massive warrant overhang: 6.1M existing warrants at $7.72 avg exercise price plus 6.1M new public warrants
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001477932-26-004044 |
| Document: 0001477932-26-004044-index-headers.html | 0001477932-26-004044 |
| Document: 0001477932-26-004044-index.html | 0001477932-26-004044 |
| Document: 0001477932-26-004044.txt | 0001477932-26-004044 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 24d ago | SC 13D | $0.9464 $0.9200 | ▼ −2.79% | ▼ −3.46% | $0.7275 (−23.13%) |
Sep 25, 2026 4w ago | 8-K | $1.01 $0.9652 | ▼ −4.44% | ▼ −4.25% | $0.7275 (−27.97%) |
Sep 17, 2026 5w ago | Press Release | $0.8775 $0.9659 | ▲ +10.07% | ▲ +10.19% | $0.7275 (−17.09%) |
Aug 20, 2026 9w ago | Press Release | $1.28 $1.31 | ▲ +2.34% | ▲ +1.93% | $0.7275 (−43.16%) |
Jul 1, 2026 16w ago | Press Release | $1.27 $1.21 | ▼ −4.72% | ▼ −4.59% | $0.7275 (−42.72%) |
Jun 30, 2026 16w ago | Press Release | $1.45 $1.27 | ▲ +12.41% | ▲ +12.28% | $0.7275 (+49.83%) |
Jun 26, 2026 17w ago | S-1/A | $0.8102 $1.45 | ▼ −78.97% | ▼ −78.19% | $0.7275 (+10.21%) |
Jun 25, 2026 17w ago | S-1 | $1.20 $0.8102 | ▼ −32.48% | ▼ −34.13% | $0.7275 (−39.37%) |
Jun 22, 2026 18w ago | Press Release | $1.93 $1.97 | ▲ +2.07% | ▲ +3.52% | $0.7275 (−62.31%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers